Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

Cantor assumes coverage of Neximmune at OW; PT $4

Cantor Fitzgerald analyst Prakhar Agrawal assumed coverage of Neximmune (NASDAQ:NEXI) with an “overweight” rating and price target of $4. The stock closed at $1.61 on June 29. Neximmune is developing a novel T-cell...

June 30, 2022

Markets

HCW starts Acumen Pharma at buy; PT $15

H.C. Wainwright initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $15 price target. The stock closed at $4.88 on June 29. Acumen is a clinical-stage biopharmaceutical company developing...

June 30, 2022

Developments

Domain Therapeutics receives multimillion-dollar milestone from Merck

Domain Therapeutics, which operates in France and Canada, obtained a single-digit multimillion-dollar milestone payment from Merck as part of a €240 million collaboration and license partnership signed in 2017. Drug...

June 30, 2022

Markets

WB cuts Aileron Therapeutics to market perform

William Blair downgraded Aileron Therapeutics (NASDAQ:ALRN) to “market perform” after the company released interim data from a Phase trial of ALRN-6924 as a chemoprotectant in patients with non-small cell lung cancer...

June 29, 2022

Developments

Palisade Bio initiates Phase 3 study for postoperative return of bowel function

Palisade Bio (NASDAQ:PALI) initiated a Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. The first clinical site in the U.S. is now open...

June 29, 2022

Executive Moves

Zymeworks names Paul Moore as CSO

Zymeworks (NYSE:ZYME) is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as chief scientific officer, reporting directly to the CEO, effective July 18. Dr. Moore brings more than 25...

June 28, 2022

Executive Moves

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

Anand Reddi, M.S. Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its board of directors, effective immediately. “Mr. Reddi and Dr. Lbiati have a remarkable wealth...

June 28, 2022

Developments

ENDRA receives 28th U.S. patent for TAEUS system

The United States Patent and Trademark Office has issued a new ENDRA Life Sciences (NASDAQ:NDRA) patent to protect its TAEUS’ radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. The...

June 28, 2022

Developments

NeuroSense posts positive results from stage 3 ALS biomarker study

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from stage 3 of its biomarker study conducted in collaboration with Massachusetts General Hospital to evaluate PrimeC, NeuroSense’s lead combination...

June 27, 2022

Markets

Cantor ups Aurora Cannabis to OW; PT up to $4.05 (Canadian)

Cantor Fitzgerald upgraded Aurora Cannabis (TSX:ACB) to “overweight” from “neutral” and raised its price target to $4.05 (Canadian) from $3.90. The stock closed at $1.84 on June 23. “We expect Europe, and more...

June 24, 2022

Markets

BTIG starts Akoya Biosciences at buy; PT $16

BTIG launched coverage of Akoya Biosciences (NASDAQ:AKYA) with a “buy” rating and $16 price target. The stock closed at $9.29 on June 21. Akoya is a rapidly growing life sciences technology company that offers a...

June 22, 2022

Developments

Zucara Therapeutics reports positive results from Phase 1b trial in T1D

Closely held Zucara Therapeutics reported that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes. Data from 18 subjects that completed all three...

June 22, 2022

Subscribe